{"filing":{"accession_number":"0001193125-26-362027","cik":"0001958777","ticker":"FBLG","company_name":"FibroBiologics, Inc.","form":"8-K","filing_date":"2026-08-24","report_date":"2026-08-20","primary_document":"fblg-20260820.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1958777/000119312526362027/fblg-20260820.htm"},"events":[{"id":29087,"run_id":26614,"accession_number":"0001193125-26-362027","anchor_item_number":"5.02","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"FibroBiologics appointed Leigh Steinberg as a Class II director effective August 20, 2026, to serve until the 2028 annual meeting. Steinberg brings 50+ years of dealmaking experience as a legendary sports agent and has long-standing advocacy for human longevity and chronic disease, areas aligned with the company's fibroblast-based therapeutic pipeline.","company_name":"FibroBiologics, Inc.","ticker":"FBLG","filing_date":"2026-08-24","form":"8-K","submitted_at":null,"items":[{"id":31245,"accession_number":"0001193125-26-362027","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of Leigh Steinberg as a Class II director of FibroBiologics, effective August 20, 2026, to serve until the 2028 annual meeting. The principal disclosed action is a person taking a board role. While the filing also mentions standard director compensation and an indemnification agreement, these are ancillary to the core appointment event. The appointment of a prominent figure with significant industry connections and negotiating experience to the board of a clinical-stage biotech company is material to investors assessing the registrant's governance and strategic direction.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-24T12:49:40.715618+00:00","company_name":"","ticker":null,"filing_date":""},{"id":31246,"accession_number":"0001193125-26-362027","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of Leigh Steinberg to FibroBiologics' Board of Directors. The press release emphasizes his extensive background as a legendary sports agent with 50+ years of dealmaking experience, his influence across sports, medicine, business and media, and his long-standing advocacy for human longevity and chronic disease—areas directly aligned with the company's fibroblast-based therapeutic pipeline. This is a material governance event affecting board composition and strategic direction.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-24T12:49:40.715618+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":31245,"accession_number":"0001193125-26-362027","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of Leigh Steinberg as a Class II director of FibroBiologics, effective August 20, 2026, to serve until the 2028 annual meeting. The principal disclosed action is a person taking a board role. While the filing also mentions standard director compensation and an indemnification agreement, these are ancillary to the core appointment event. The appointment of a prominent figure with significant industry connections and negotiating experience to the board of a clinical-stage biotech company is material to investors assessing the registrant's governance and strategic direction.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-24T12:49:40.715618+00:00","company_name":"FibroBiologics, Inc.","ticker":"FBLG","filing_date":"2026-08-24"},{"id":31246,"accession_number":"0001193125-26-362027","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of Leigh Steinberg to FibroBiologics' Board of Directors. The press release emphasizes his extensive background as a legendary sports agent with 50+ years of dealmaking experience, his influence across sports, medicine, business and media, and his long-standing advocacy for human longevity and chronic disease—areas directly aligned with the company's fibroblast-based therapeutic pipeline. This is a material governance event affecting board composition and strategic direction.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-24T12:49:40.715618+00:00","company_name":"FibroBiologics, Inc.","ticker":"FBLG","filing_date":"2026-08-24"}]}